In recent years, human cell models have become a potential game-changer in the way we test drugs and model diseases. Because these models are human-based they often predict patient response more accurately when exposed to drugs compared to animal-based models. In addition, such models can also be made from healthy or sick individuals. This makes it possible to do personalized drug testing or therapy selection. Typically, stem cells are used from which mini-organs or organoids can be made. While the biotechnology to make such models has been improved majorly in the last decade, technology to automate and accurately control these models is still lacking – limiting their robustness and uptake by end users such as pharmaceutical companies.
About Demcon biovitronix
Demcon biovitronix has been founded in 2022 with the aim to bring Organs-on-Chips and Microphysiological Systems to real-world applications. Being part of the Demcon group, the company has access to an extensive source of engineering and data analytics knowledge. We strongly believe that with high tech engineering we can improve current biological assays by introducing precise control, (pharma)kinetics and continuous readout of biological in vitro model systems. Drug testing and disease modelling can become easier and more reliable with the right technological tools. We create a bridge between in vitro biology, microfluidics and mechatronics to add possibilities to existing assays without increasing the complexity of protocols.
"we want to make Organ-on-Chip an accessible technology.
Organ-on-Chip has the potential to revolutionize the way we study diseases and treat patients. We could use it to find treatments that are tailored for a specific patient. However, at present time, you need to be an expert in Organ-on-Chip to get it to work. It is not automated and it disrupts the current laboratory workflows. We are here to change that making use of automation, mechatronics and our experience in in vitro biology.